← back to search

Gabriela Chiosis

Memorial Sloan Kettering Cancer Center · US
Area of research
Molecular Biology · Computational Theory and Mathematics
Research interest
Research interests include Heat shock proteins research, Computational Drug Discovery Methods, Endoplasmic Reticulum Stress and Disease, and Protein Structure and Dynamics.
h-index
66
citations
15,135
works
386
NIH funding
primary concept
email

Recent publications

PTMs as molecular encoders: reprogramming chaperones into epichaperomes for network control in disease
Trends in Biochemical Sciences 2025cited by 8position: lastdoi
Phosphorylation-driven epichaperome assembly is a regulator of cellular adaptability and proliferation
Nature Communications 2024cited by 26position: middledoi
Stress biology: Complexity and multifariousness in health and disease
Cell Stress and Chaperones 2024cited by 6position: middledoi
Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation
Nature Communications 2023cited by 44position: lastdoi
RNA binding protein SYNCRIP maintains proteostasis and self-renewal of hematopoietic stem and progenitor cells
Nature Communications 2023cited by 20position: middledoi
Targeting stressor-induced dysfunctions in protein–protein interaction networks via epichaperomes
Trends in Pharmacological Sciences 2022cited by 31position: lastdoi
The penalty of stress ‐ Epichaperomes negatively reshaping the brain in neurodegenerative disorders
Journal of Neurochemistry 2021cited by 34position: lastdoi
Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system
Nature Communications 2021cited by 33position: lastdoi
Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer
Communications Biology 2021cited by 26position: lastdoi
Disease‐specific interactome alterations via epichaperomics: the case for Alzheimer’s disease
FEBS Journal 2021cited by 25position: lastdoi
Gold/alpha-lactalbumin nanoprobes for the imaging and treatment of breast cancer
Nature Biomedical Engineering 2020cited by 94position: middledoi
The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction
Nature Communications 2020cited by 85position: lastdoi
Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone
Cell Reports 2020cited by 61position: lastdoi
Paradigms for Precision Medicine in Epichaperome Cancer Therapy
Cancer Cell 2019cited by 59position: middledoi
Reply to ‘H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines’
Nature Genetics 2019cited by 18position: middledoi
Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia
Nature Medicine 2018cited by 88position: middledoi
HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons
Nature Communications 2018cited by 56position: middledoi
Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors
The Journal of Experimental Medicine 2017cited by 193position: middledoi
Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
Molecular Cancer Therapeutics 2017cited by 94position: middledoi
The epichaperome is an integrated chaperome network that facilitates tumour survival
Nature 2016cited by 302position: lastdoi
Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas
Blood 2015cited by 99position: middledoi
Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models
Molecular Imaging and Biology 2015cited by 96position: middledoi
Structure–Activity Relationship in a Purine-Scaffold Compound Series with Selectivity for the Endoplasmic Reticulum Hsp90 Paralog Grp94
Journal of Medicinal Chemistry 2015cited by 65position: lastdoi
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species
Cell Reports 2015cited by 63position: middledoi
Abstract 1435: Role of PRKD2 in HSP90- and hypoxia-mediated epithelial-to-mesenchymal transition
Cancer Research 2015cited by 0position: middledoi
Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions
Expert Opinion on Investigational Drugs 2014cited by 172position: lastdoi
HSP90 Supports Tumor Growth and Angiogenesis through PRKD2 Protein Stabilization
Cancer Research 2014cited by 56position: middledoi
Abstract 5129: Role of PRKD2 in HSP90 inhibition-mediated suppression of cancer growth
Cancer Research 2014cited by 0position: middledoi
Protein kinase D2 modulates tumor growth and tumor angiogenic programme induced by heat shock protein 90
Zeitschrift für Gastroenterologie 2014cited by 0position: middledoi
Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2
Nature Chemical Biology 2013cited by 212position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Claudia Scholl · German Cancer Research Center6 papers (2012–2015) · 6 papers (2012–2015) · 5 papers (2013–2017) · 5 papers (2012–2014)Stefan Fröhling · German Cancer Research Center5 papers (2012–2015)Stephen D. Ginsberg · New York University4 papers (2021–2025)Pengrong Yan · UPMC Hillman Cancer Center4 papers (2013–2021) · 4 papers (2014–2015)Hans A. Kestler · Johannes Gutenberg University Mainz4 papers (2012–2014)Sahil Sharma · Purdue University West Lafayette3 papers (2021–2025) · 3 papers (2014–2015)Thomas Seufferlein · Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie3 papers (2014–2015)Tai Wang · Tianjin University3 papers (2020–2021)Johan Van Lint · KU Leuven3 papers (2014–2014)John Koren · University of South Florida3 papers (2014–2015) · 3 papers (2020–2023)A. MAUREEN ROUHI · BC Cancer Agency3 papers (2014–2014) · 3 papers (2015–2017)Stefan O. Ochiana · Northeastern University3 papers (2014–2015) · 3 papers (2014–2015)